Lower incidence of Pneumocystis jirovecii pneumonia among Africans in the Netherlands host or environmental factors?

AIDS

Volumn 27, Issue 7, 2013, Pages 1179-1184

  Schoffelen, Annelot F ^a   Van Lelyveld, Steven F L ^a   Barth, Roos E ^a   Gras, Luuk ^b   De Wolf, Frank ^b   Netea, Mihai G ^c   Hoepelman, Andy I M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b STICHTING HIV MONITORING   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Ethnicity; Genetic susceptibility; HIV; HIV related opportunistic infections; Pneumocystis jirovecii; Pneumocystis pneumonia

Indexed keywords

VIRUS RNA;

ADULT; AFRICA; AFRICAN AMERICAN; AGE; ARTICLE; AUSTRALIA; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; ENVIRONMENTAL FACTOR; EUROPE; FEMALE; FOLLOW UP; GEOGRAPHY; HETEROSEXUALITY; HOMOSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; NEW ZEALAND; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; VIRUS TRANSMISSION;

AFRICA SOUTH OF THE SAHARA; AGE DISTRIBUTION; AIDS-RELATED OPPORTUNISTIC INFECTIONS; CD4 LYMPHOCYTE COUNT; EMIGRANTS AND IMMIGRANTS; FEMALE; FOLLOW-UP STUDIES; GENE-ENVIRONMENT INTERACTION; GENETIC PREDISPOSITION TO DISEASE; HIV INFECTIONS; HUMANS; INCIDENCE; MALE; NETHERLANDS; ODDS RATIO; PNEUMOCYSTIS JIROVECII; PNEUMONIA, PNEUMOCYSTIS; RETROSPECTIVE STUDIES; VIRAL LOAD;

EID: 84879103379     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32835e2c90     Document Type: Article

References (22)

1. Kelley CF, Checkley W, Mannino DM, Franco-Paredes C, Del Rio C, Holguin F. Trends in hospitalizations for AIDS-associated Pneumocystis jirovecii pneumonia in the United States (1986 to 2005). Chest 2009; 136:190-197.
2. Benito N, Moreno A, Miro JM, Torres A. Pulmonary infections in HIV-infected patients: an update in the 21st century. Eur Respir J 2012; 39:730-745.
3. Buchacz K, Baker RK, Palella FJ Jr, Chmiel JS, Lichtenstein KA, Novak RM, et al. AIDS-defining opportunistic illnesses in US patients, 1994-2007: a cohort study. Aids 2010; 24:1549-1559.
4. Morris A, Lundgren JD, Masur H, Walzer PD, Hanson DL, Frederick T, et al. Current epidemiology of Pneumocystis pneumonia. Emerg Infect Dis 2004; 10:1713-1720.
5. Malin AS, Gwanzura LK, Klein S, Robertson VJ, Musvaire P, Mason PR. Pneumocystis carinii pneumonia in Zimbabwe. Lancet 1995; 346:1258-1261.
6. Fisk DT, Meshnick S, Kazanjian PH. Pneumocystis carinii pneumonia in patients in the developing world who have acquired immunodeficiency syndrome. Clin Infect Dis 2003; 36:70-78.
7. Del Amo J, Petruckevitch A, Phillips AN, Johnson AM, Stephenson JM, Desmond N, et al. Spectrum of disease in Africans with AIDS in London. AIDS 1996; 10:1563-1569.
8. Stansell JD, Osmond DH, Charlebois E, LaVange L, Wallace JM, Alexander BV, et al. Predictors of Pneumocystis carinii pneumonia in HIV-infected persons. Pulmonary Complications of HIV Infection Study Group. Am J Respir Crit Care Med 1997; 155:60-66.
9. Hu DJ, Fleming PL, Castro KG, Jones JL, Bush TJ, Hanson D, et al. How important is race/ethnicity as an indicator of risk for specific AIDS-defining conditions? J Acquir Immune Defic Syndr Hum Retrovirol 1995; 10:374-380.
10. Kaplan JE, Hanson DL, Navin TR, Jones JL. Risk factors for primary Pneumocystis carinii pneumonia in human immunodeficiency virus-infected adolescents and adults in the United States: reassessment of indications for chemoprophylaxis. J Infect Dis 1998; 178:1126-1132.
11. van Sighem A, Smit C, Gras L, Holman R, Stolte I, Prins M, et al. Monitoring of human immunodeficiency virus (HIV) infection in the Netherlands. Monitor Rep 2011. http://www.hiv-monitoring.nl/english/research/ monitoringrapporten/ (Accessed on 7 September 2012).
12. World Health Organization. WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children. 2007. http://www.who.int/hiv/pub/guidelines/ HIVstaging150307.pdf (Accessed on 7 September 2012).
13. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007; 370:1453-1457.
14. Smulian AG, Sullivan DW, Linke MJ, Halsey NA, Quinn TC, MacPhail AP, et al. Geographic variation in the humoral response to Pneumocystis carinii. J Infect Dis 1993;167:1243-1247.
15. Morris A, Norris KA. Colonization by Pneumocystis jirovecii and its role in disease. Clin Microbiol Rev 2012; 25:297-317.
16. Beard CB, Carter JL, Keely SP, Huang L, Pieniazek NJ, Moura IN, et al. Genetic variation in Pneumocystis carinii isolates from different geographic regions: implications for transmission. Emerg Infect Dis 2000; 6:265-272.
17. Ashton LJ, Stewart GJ, Biti R, Law M, Cooper DA, Kaldor JM. Heterozygosity for CCR5-delta32 but not CCR2b-64I protects against certain intracellular pathogens. HIV Med 2002; 3:91-96.
18. An P, Li R, Wang JM, Yoshimura T, Takahashi M, Samudralal R, et al. Role of exonic variation in chemokine receptor genes on AIDS: CCRL2 F167Y association with pneumocystis pneumonia. PLoS Genet 2011; 7:e1002328.
19. Forthal DN, Landucci G, Bream J, Jacobson LP, Phan TB, Montoya B. FcgammaRIIa genotype predicts progression of HIV infection. J Immunol 2007; 179:7916-7923.
20. Dennehy KM, Brown GD. The role of the beta-glucan receptor Dectin-1 in control of fungal infection. J Leukoc Biol 2007; 82:253-258.
21. Saijo S, Fujikado N, Furuta T, Chung SH, Kotaki H, Seki K, et al. Dectin-1 is required for host defense against Pneumocystis carinii but not against Candida albicans. Nat Immunol 2007; 8:39-46.
22. Netea MG, Wijmenga C, O'Neill LA. Genetic variation in Tolllike receptors and disease susceptibility. Nat Immunol 2012; 13:535-542.